Biotech: Page 24
-
Permission granted by Marea Therapeutics
Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it.
With a drug licensed from Novartis, the new biotech startup aims to reduce the ‘remnant’ cholesterol it says existing medicines can’t address.
By Gwendolyn Wu • June 18, 2024 -
Maximusnd via Getty Images
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments
The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.
By Jacob Bell • June 17, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Love Employee via Getty Images
Immune resetNew data showcase promise, growing pains of CAR-T in autoimmune disease
One expert described trial results presented at EULAR in June as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.
By Ben Fidler • June 17, 2024 -
Courtesy of AbbVie
AbbVie joins in latest gastrointestinal drug chase
Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.
By Jonathan Gardner • June 14, 2024 -
Michael M. Santiago via Getty Images
Radiopharma drugmaker Telix pulls US IPO plans
The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange.
By Ned Pagliarulo • June 14, 2024 -
Daniel Tadevosyan via Getty Images
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.
By BioPharma Dive staff • June 14, 2024 -
Joe Raedle/Getty Images via Getty Images
Moderna says next-gen COVID shot effective in study
Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.
By Kristin Jensen • June 13, 2024 -
Permission granted by Versant Ventures
Versant debuts biotech working on ‘anger management for the immune system’
Investor enthusiasm for precision immunology medicines is providing a tailwind for Santa Ana Therapeutics, a new startup backed by Versant, GV and a16z, among others.
By Gwendolyn Wu • June 13, 2024 -
Jeenah Moon via Getty Images
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.
By Delilah Alvarado • June 12, 2024 -
Igor Kutyaev via Getty Images
Regenxbio CEO to step down after 15 years
Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.
By Ned Pagliarulo • June 12, 2024 -
Permission granted by Ultragenyx
Ultragenyx, Mereo drug reduces fractures in bone disorder study
New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.
By Kristin Jensen • June 12, 2024 -
Daniel Tadevosyan via Getty Images
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.
By BioPharma Dive staff • June 12, 2024 -
Pla2Na via Getty Images
Foresite, a biotech venture firm, reloads with $900M fund
Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.
By Gwendolyn Wu • June 12, 2024 -
Rasi Bhadramani via Getty Images
Ipsen drug for rare liver disease approved by FDA
The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.
By Ned Pagliarulo • June 11, 2024 -
Michael M. Santiago via Getty Images
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
The offering will help fund Phase 3 tests of a drug the biotech claims could be more selective and potent than Bristol’s TYK2 inhibitor.
By Ben Fidler • June 10, 2024 -
Daniel Tadevosyan via Getty Images
Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO
After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.
By BioPharma Dive staff • June 7, 2024 -
Warren Little via Getty Images
GSK acquires oligonucleotide drug startup Elsie
The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.
By Delilah Alvarado • June 6, 2024 -
Gwendolyn Wu/BioPharma Dive
As biotech recovers, venture firms’ preferences appear to shift
Venture investment into U.S. biotechs is back at pre-COVID levels. But firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs for an exit.
By Gwendolyn Wu • Updated June 6, 2024 -
Lark Andrew Balcita via Getty Images
Germany’s ITM raises $205M as radiopharma field booms
The funding will help ITM advance a pipeline that includes a potential competitor to Novartis' neuroendocrine cancer treatment Lutathera.
By Ned Pagliarulo • June 6, 2024 -
Daniel Tadevosyan via Getty Images
Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.
By BioPharma Dive staff • June 5, 2024 -
Dr_Microbe via Getty Images
Viking says biopsy data confirm MASH drug’s benefit
The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.
By Jonathan Gardner • June 4, 2024 -
Spencer Platt via Getty Images
Structure pill leads to competitive weight loss in obesity study
Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.
By Delilah Alvarado • June 3, 2024 -
JHVEPhoto via Getty Images
ALS drug developmentEli Lilly adds ALS drug prospect with QurAlis deal
The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.
By Gwendolyn Wu • June 3, 2024 -
Daniel Tadevosyan via Getty Images
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.
By BioPharma Dive staff • May 31, 2024 -
Getty Images via Getty Images
Immunovant changes up plans for closely watched autoimmune drugs
The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions.
By Kristin Jensen • May 30, 2024
Previous
